Literature DB >> 2144441

Interim analyses in clinical trials.

S S Emerson1, T R Fleming.   

Abstract

Clinical trials of new cancer treatments often involve multiple analyses of the data to address concerns related to medical ethics and the costs and efficiency of medical research. Failure to account for such interim analyses can introduce significant bias into the results of a study. The authors discuss the role of interim analyses in clinical trials and describe the factors that need to be considered in the planning, monitoring, and reporting of a study involving group sequential hypothesis tests.

Entities:  

Mesh:

Year:  1990        PMID: 2144441

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  3 in total

1.  Monitoring for lack of benefit: a critical component of a randomized clinical trial.

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

2.  A trial of an impedance threshold device in out-of-hospital cardiac arrest.

Authors:  Tom P Aufderheide; Graham Nichol; Thomas D Rea; Siobhan P Brown; Brian G Leroux; Paul E Pepe; Peter J Kudenchuk; Jim Christenson; Mohamud R Daya; Paul Dorian; Clifton W Callaway; Ahamed H Idris; Douglas Andrusiek; Shannon W Stephens; David Hostler; Daniel P Davis; James V Dunford; Ronald G Pirrallo; Ian G Stiell; Catherine M Clement; Alan Craig; Lois Van Ottingham; Terri A Schmidt; Henry E Wang; Myron L Weisfeldt; Joseph P Ornato; George Sopko
Journal:  N Engl J Med       Date:  2011-09-01       Impact factor: 91.245

3.  Stopping rules, interim analyses and data monitoring committees.

Authors:  D Ashby; D Machin
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.